Antigenic site changes in the rabies virus glycoprotein dictates functionality and neutralizing capability against divergent lyssaviruses.
Introduction 44
The lyssaviruses constitute virus genus of importance to both human and animal health. All 45 viruses within this genus are highly neurotropic and are capable of causing a fatal disease 46 resulting in encephalitis, known as rabies [1] . The lyssavirus genus is classified within the 47 Order Mononegavirales, Family Rhabdoviridae and comprises 16 proposed species. 48 Lyssaviruses have non-segmented (single-stranded) negative sense genomes of between 11-49 12kbp. The genome encodes 5 proteins: the nucleocapsid (N) protein, the phosphoprotein (P), 50 the matrix protein (M), the glycoprotein (G) and the large polymerase protein (L). The 51 prototypic lyssavirus is rabies virus (RABV), which is primarily transmitted through the bite 52 of an infected animal and causes a higher burden of disease in both humans and animals than 53 any other lyssavirus. Members of the lyssavirus genus are able to infect and cause disease in 54 a wide host range, with theoretically all mammalian species being susceptible to infection [2] . 55 It is estimated that more than 60,000 people die from rabies annually [1, [3] [4] [5] . Despite safe 56 and effective prophylactic and post-exposure tools being available RABV remains endemic 57 across much of Africa and Asia. Fourteen of the 16 proposed lyssaviruses have been 58 associated with the infection of bat species and chiropteran species are generally considered 59 to be the reservoir for the lyssaviruses [6, 7] . Infection of humans with non-RABV 60 lyssaviruses appears to be rare with only 13 human fatalities being documented [8] .
The target for neutralising antibody responses against all lyssaviruses is the surface 93 glycoprotein (G). This protein is the major viral component responsible for the induction of a 94 host antibody response and is thought to be the sole target of host neutralising antibodies 95 [24] . Studies with the RABV G protein have defined four major antigenic sites and one minor 96 antigenic site [25] [26] [27] [28] [29] [30] [31] [32] [33] . These regions include four continuous epitopes and a discontinuous 97 conformational epitope proposed to be formed through the interaction of two distinct regions 98 (antigenic sites IIa and IIb) within the mature protein. The relative importance of each site for 99 neutralisation of RABV has been previously measured using crude estimates of the number 100 of monoclonal antibodies specific to each site, but not with polyclonal sera. Although 101 important in RABV neutralisation, there is currently no evidence to suggest that the same 102 regions have a similar function within the other lyssaviruses. Still, whilst there is no structural 103 model for the lyssavirus glycoprotein, alignments with the Vesicular Stomatitis Virus pre-104 and post-fusion glycoprotein structures [34, 35] at least suggest that these antigenic sites are 105 present on the exposed surfaces of the glycoprotein. However, the role of these antigenic sites 106 is undefined, hampering assessment of the threat posed by emerging lyssaviruses, and 107 vaccine design. In this study, the importance of these RABV antigenic epitopes for virus 108 neutralisation across the lyssavirus genus was assessed, using data from both pseudotype 109 viruses and recombinant lyssaviruses generated by reverse genetics. This study demonstrates 110 that individual antigenic sites are highly specific in generating the differential neutralisation 111 pattern seen between the proposed lyssavirus phylogroups against the lyssavirus G protein. To assess the ability of sera from vaccinated humans and animals to neutralise all viruses 116 within phylogroup I, a panel of PTVs was generated to enable the assessment of a 117 representative of each lyssavirus species. Two types of RABV specific sera were assessed 118 against this panel: WHO serum, an international standard sera prepared from blood sampled 119 from vaccinated humans that is used as control sera for WHO gold standard serological 120 assays; and Veterinary Laboratories Agency (VLA) serum, a diagnostic control serum 121 obtained from a pool of serum from vaccinated dogs used in serological diagnostic tests 122 performed at APHA, UK. Both sera were used at a dilution of 0.5 IU/ml, the WHO and OIE 123 internationally accepted cut-off titre for seroconversion [9] and a more stringent threshold of 124 0.1 IU/ml according to dilutions assessed using live virus in the Fluorescent Antibody Virus 125 Neutralisation test (FAVN). The PNA was used to assess the ability of WHO and VLA sera 126 to neutralise each phylogroup I PTV ( Figure 1 ) and all were neutralised by >90% by these 127 sera. Furthermore, all of the phylogroup I PTVs were also completely neutralised by WHO 128 and VLA sera at 0.1 IU/ml. (Supplementary Figure 1) .
130
A humoral response to phylogroup II lyssaviruses neutralises other phylogroup II PTVs
131
To investigate the degree of cross neutralisation between viruses within phylogroup II, 132 specific sera had to be generated specific for phylogroup II. A PTV expressing LBV lineage 133 B G was selected for inoculation into rabbits to generate sera specific for this G protein.
134
Representative PTVs for all available lyssavirus phylogroups were successfully generated. Alterations to antigenic domains within the lyssavirus G affect both functionality and 147 neutralisation profiles of the mutated proteins.
148
To further investigate the relative importance the five defined antigenic epitopes, a series of 149 recombinant PTVs were developed that had the defined antigenic epitopes swapped between 150 a phylogroup I virus (CVS) and a phylogroup II virus (LBV lineage B). Both individual 151 antigenic site mutants [36] were utilised alongside G proteins that had all five antigenic 152 epitopes exchanged between the two viruses ( Figure 3 ). Once plasmids had been constructed, 153 the ability to generate PTs with each of the single site swaps (SSS) was assessed alongside 154 the ability to generate the full site swap (FSS) mutants. Initially, functionality of mutated 155 forms of the G protein were assessed through their relative ability to generate titres as PTVs.
156
Then, where titres were achieved, the ability of standard sera to neutralise these recombinant 157 PTVs were assayed. All attempts to generate a PTV containing the CVS G with all five 158 antigenic sites being swapped with those of LBV (CVSFSS) failed to generate titres of 200 159 TCID50/ml and so could not be used in the PNA. LBV specific sera. Each of the single site swap PTVs were neutralised by the LBV specific 178 sera although some of the mutants, LBV to CVS sites I, IIb, IIaIIb and III, were neutralised 179 to a greater degree by the RABV sera than the LBV sera suggesting that these epitopes may 180 play more prominent roles in neutralisation. To further investigate the role of antigenic epitopes in the G protein, a series of mutated and 185 wildtype PTVs were inoculated into rabbits to generate sera specific for each mutant. Four 186 mutant PTVs were selected, CVS to LBV I, LBV to CVS I, LBV to CVS IIaIIb and 187 LBVFSS, on the basis of earlier results. The CVS to LBV I, LBV to CVS I, LBV to CVS 188 IIaIIb and LBVFSS specific sera were run against wildtype CVS and LBV PTVs at 0.5 IU/ml 189 ( Figure 4 ). The CVS to LBV I serum neutralised the CVS PTV but also neutralised the LBV 190 PTV by 47%. In the reciprocal experiment the LBV to CVS I serum completely neutralised 191 the LBV PTV but only neutralised the CVS PTV by 7%. Interestingly, the LBV to CVS IIaIIb serum neutralised the CVS PTV more strongly than the LBV PTV; by 93% and 64%, 193 respectively. Finally, the LBVFSS specific serum neutralised both CVS and LBV PTVs to a 194 similar extent; 51% and 56% respectively. The observation that the CVSFSS PTV could not be generated, even following back mutation 198 of sites IIa and IIb, led to speculation that the mutations incorporated into the glycoprotein 199 had rendered it non-functional. Interestingly, the LBVFSS PTV could be generated and Data generated here using the PTV assay confirmed that cross neutralisation occurs within 291 phylogroup I using standardised sera at both 0.5 IU and 0.1U/ml. This corroborates existing 292 studies and suggests cross neutralisation within phylogroup I, both to a protective titre of 293 anti-RABV serum but also to an apparently sub-protective but clearly neutralising dilution of 294 serum. Previous studies have suggested that antibody titres lower than the internationally 295 recognised cut-off (0.5IU/ml) are protective although test sensitivity makes a precise 296 definition of this cut-off difficult [9, 40] . Regardless, varying levels of cross neutralisation 297 within phylogroup I have been demonstrated previously whereby vaccination with the 298 Human Diploid Culture Vaccine (HDCV) was able to protect more efficiently against CVS 299 and EBLV-2 infection than ABLV or EBLV-1 [21, 22] . Antigenic cartography has further 300 enabled assessment of antigenicity and studies have suggested that ABLV and KHUV may 301 be antigenically identical to the RABV isolates assessed. IRKV, ARAV and EBLV-1 are also 302 believed to be closely related antigenically to RABV with EBLV-2 being more divergent 303 amongst the isolates assessed [12] . Several studies have suggested a need for higher 304 neutralising antibody titres to effectively neutralise non rabies phylogroup I lyssaviruses [22] .
305
A single report of rabies vaccination protecting a dog from a phylogroup II virus exists the rhabdovirus virion represents a highly ordered bullet shaped virion with peplomers of 312 trimeric G studded tightly across its surface. As such it is clear that the neutralisation of one 313 is likely more readily achieved than the other. Certainly, this increased sensitivity of the PNA 314 is something that has been observed before with influenza and lyssavirus PTVs [41, 42] and where sera have been suggested to be highly specific for individual lyssaviruses. Sera from 332 76 insectivorous bats that reacted against WCBV were unable to neutralise other lyssaviruses, 333 including LBV, MOKV, RABV and DUVV. Interestingly, a serum sample from a single bat 334 also strongly neutralised DUVV [13] . Partial cross neutralisation of WCBV and IKOV by the 335 LBV lineage B specific serum was observed in this study suggesting some cross 336 neutralisation even where 54% (WCBV) and 48% (IKOV) amino acid identity is seen.
337
Previous investigations indicated that antibodies induced by rabies vaccination provide no 338 protection against infection with phylogroup II or III viruses, even at concentrations 20 times 339 greater than those which neutralise phylogroup I constructs [18, 19] . This likely reflects that Figure 2) suggested that sites I, III and IV were less important for 387 neutralisation by serum specific to LBV B. LBV to CVS I serum did not neutralise CVS 388 PTV whereas the LBV B to CVS IIaIIb serum did (Figure 4 ). This suggests that site II is 389 more important than site I in stimulating a specific antibody response. The LBVFSS serum 390 was able to neutralise both CVS PTV and LBV PTV by approximately 50% (Figure 4) which 391 was in contrast to the ability of both RABV and LBV specific sera to strongly neutralise 392 LBVFSS PTV (Supplementary Figure 3) . The differences between these neutralisation 393 profiles may be due to individual differences in response to the antigens driven by innate 394 differences between rabbit and mouse immune responses as the antigenic sites were 395 originally mapped using murine antibodies [25] . Results may also be skewed through The present study has indicated that: individual antigenic sites within the lyssavirus G can 436 affect neutralisation profiles; pseudotype particles may be utilised as potential vaccine 437 candidates but have limitations when assessing neutralising profiles; and importantly that 438 immunodominant epitopes identified through monoclonal antibody mapping can differ when 439 comparing responses to whole antigen in polyclonal sera. This latter point is of potential 440 significance as the determination of immunodominant epitopes through monoclonal antibody 441 binding is an artificial process in comparison to protein structure recognition by polyclonal sera. Certainly, it is likely that other, undefined immunologically important epitopes outside 443 of those assessed here influence the repertoire of neutralising antibodies produced following 444 vaccination. Regardless, the continued discovery of lyssaviruses that are genetically closely 445 related to RABV [51] as well as those that are highly divergent [16] drives the need for 446 further investigation into factors that contribute to a protective immune response across the 447 genus. In conclusion, whilst rabies constitutes the biggest threat to human and animal health, 
Materials and Methods

452
Cells Baby hamster kidney cells (BHK-21) and Human embryonic kidney cells (HEK 453 293T/17) were grown and maintained as described previously [52] . All cell lines were 454 maintained at 37°C in a 5% CO2 incubator (Binder). percentage neutralisation test, the degree of neutralisation was calculated as a reduction in the 467 level of luminescence compared to virus not exposed to serum. Each assay was carried out in 468 triplicate and a mean average percentage neutralisation was calculated. For the serum titre 469 test the 50% end point dilution (where complete neutralisation stopped in 50% of the wells) 470 was also calculated using the Spearman-Kärber method [53] . Back titration of PTV was 471 carried out alongside each PNA using the same method as that for initial titration to ensure 472 consistent input of PTV. FuGENE6. Plates were incubated for 48-72 hours prior to harvest. Rescued virus was 490 passaged until 100% infectivity was reached and titrated as previously described [54] . Virus 491 titres were determined as focus forming units per ml (ffu/ml). Multistep growth curves were conducted as previously described [38] . At each required time point, 100µl of supernatant 493 was harvested, frozen at -80°C then thawed and titrated in triplicate on BHK cells. Generation of PTV specific sera in rabbits A panel of PTVs containing wildtype or 503 mutated lyssavirus G proteins was generated and inactivated by the addition of β-504 propriolactone (1/4000 final dilution) and incubation at 4°C for 19 hours followed by 1 hour 505 at 37°C. Aliquots of inactivated PTV were stored at -20°C until required. Each PTV was 506 mixed with Montanide™ ISA 50 V2 (Seppic) at a 1:1 ratio prior to inoculation. One rabbit 507 was inoculated per PTV. Prior to administration, inoculation sites were shaved and Emla 508 cream (AstraZeneca) was applied. Each rabbit was inoculated at four sites subcutaneously 509 followed by two sites intramuscularly on days 0, 21, 28 and 35. On day 43 all rabbits were 510 anaesthetised and blood was removed via cardiac puncture under terminal anaesthesia.
511
Following collection, blood was subjected to centrifugation at 2500 rpm (860 x g) for 10 512 minutes, and cleared serum was harvested. Sera were heat inactivated at 56°C for 30 minutes 513 then divided across 500µl aliquots and stored at -20°C until required. Mice Three to four week old female CD1 mice (Charles River) were microchipped using 517 Trovan chips to enable identification and housed as described above. This study was funded by DEFRA grant SE0426 and SE0431. The funders had no role in 560 study design, data collection and interpretation, or the decision to submit the work for 561 publication. JSE was supported in a PhD studentship through this grant. We thank the animal 562 care staff at APHA for assistance with experimentation and the APHA Animal Welfare ethics 563 Review Board for ethical appraisal of studies. with antigenic mutant PTVs. The four sera directed against antigenic site swap mutants 720 were diluted to 0.5 IU/ml and run against wildtype CVS and LBV PTVs. A 2-way ANOVA 721 was used to determine any significant differences between neutralisation of each PTV by the test sera compared to the lack of neutralisation by negative dog serum (0% neutralisation by 723 negative dog serum not shown). Significant differences are indicated by asterisks; *p≤0.05.
724
Error bars represent standard deviation about the mean of three replicate in-assay 725 neutralisation tests. 
